NYXH

Company Overview — What Does Nyxoah SA Do?

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Nyxoah SA (NYXH) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Olivier Taelman and employs approximately 110 people. With a market capitalization of $138M, NYXH is one of the notable companies in the Healthcare sector.

Nyxoah SA (NYXH) Stock Rating — Avoid (April 2026)

As of April 2026, Nyxoah SA receives a Avoid rating with a composite score of 29.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.NYXH ranks #4,157 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nyxoah SA ranks #732 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NYXH Stock Price and 52-Week Range

Nyxoah SA (NYXH) currently trades at $2.86. The stock lost $0.01 (0.3%) in the most recent trading session. The 52-week high for NYXH is $11.87, which means the stock is currently trading -75.9% from its annual peak. The 52-week low is $3.05, putting the stock -6.2% above its annual trough. Recent trading volume was 38K shares, suggesting relatively thin trading activity.

Is NYXH Overvalued or Undervalued? — Valuation Analysis

Nyxoah SA (NYXH) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.23x, versus the sector average of 2.75x. The price-to-sales ratio is 7.70x, compared to 1.66x for the average Healthcare stock.

At current multiples, Nyxoah SA trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nyxoah SA Profitability — ROE, Margins, and Quality Score

Nyxoah SA (NYXH) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -209.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -149.6% versus the sector average of -33.1%.

On a margin basis, Nyxoah SA reports gross margins of 65.7%, compared to 71.5% for the sector. The operating margin is -1300.8% (sector: -66.1%). Net profit margin stands at -1310.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NYXH Debt, Balance Sheet, and Financial Health

Nyxoah SA has a debt-to-equity ratio of 2.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $3M. Cash and equivalents stand at $35M.

NYXH has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Nyxoah SA is 40/100, reflecting average volatility within the normal range for its sector.

Nyxoah SA Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nyxoah SA reported revenue of $5M. Net income for the quarter was $-61M. Gross margin was 65.7%. Operating income came in at $-61M.

In FY 2024, Nyxoah SA reported revenue of $5M. Net income for the quarter was $-61M. Gross margin was 65.7%. Revenue grew -2.7% year-over-year compared to FY 2023. Operating income came in at $-61M.

In FY 2023, Nyxoah SA reported revenue of $5M. Net income for the quarter was $-48M. Gross margin was 61.9%. Revenue grew -54.3% year-over-year compared to FY 2022. Operating income came in at $-50M.

In FY 2022, Nyxoah SA reported revenue of $11M. Net income for the quarter was $-33M. Gross margin was 62.7%. Operating income came in at $-28M.

Over the past 6 quarters, Nyxoah SA has demonstrated a growth trajectory, with revenue expanding from $0 to $5M. Investors analyzing NYXH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NYXH Dividend Yield and Income Analysis

Nyxoah SA (NYXH) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NYXH Momentum and Technical Analysis Profile

Nyxoah SA (NYXH) has a momentum factor score of 21/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

NYXH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nyxoah SA (NYXH) ranks #732 out of 838 stocks based on the Blank Capital composite score. This places NYXH in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NYXH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NYXH vs S&P 500 (SPY) comparison to assess how Nyxoah SA stacks up against the broader market across all factor dimensions.

NYXH Next Earnings Date

No upcoming earnings date has been announced for Nyxoah SA (NYXH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NYXH? — Investment Thesis Summary

The quantitative profile for Nyxoah SA suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 21/100, a headwind for near-term performance.

In summary, Nyxoah SA (NYXH) earns a Avoid rating with a composite score of 29.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NYXH stock.

Related Resources for NYXH Investors

Explore more research and tools: NYXH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NYXH head-to-head with peers: NYXH vs AZN, NYXH vs SLGL, NYXH vs VMD.